MarketPulse
R

$RGC

3 articles found
0 positive
3 negative
0 neutral
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Regencell's 21,000% Surge Masks Fundamental Risks in Unproven Biotech

Regencell Bioscience surged 21,000% despite zero revenue and no approved products, exemplifying speculative excess that investors should avoid.
PFERGCpenny stockdrug development
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Shareholder Law Firm Probes Regencell, Camping World Over Securities Violations

Shareholder law firm investigates Regencell and Camping World for securities violations. Regencell faces DOJ trading probe; Camping World disclosed accounting restatements, Q4 losses, and suspended dividends.
CWHRGCshareholder rightssecurities investigation
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Pfizer's Boring Appeal: Why Blue-Chip Stability Beats Biotech Hype

Pfizer's reasonable valuation, robust pipeline, and 6.4% dividend yield offer disciplined returns versus speculative biotech like Regencell, whose 21,000% surge lacks fundamental justification.
PFERGCstock valuationclinical trials